Fig. 1.
Prognostic value of ABCA6 in primary EWS patients. a, Prognostic impact of ABCA6 expression according to Kaplan–Meier curves and log-rank test in 78 EWS cases analyzed by RT-qPCR. Samples with high (H) and low (L) expression were defined according to the median value. Relapse-free survival (RFS) and overall survival (OS) were evaluated. The time scale refers to months from diagnosis. The number of patients at risk in the H and L groups is listed below each time interval. b, Kaplan–Meier analysis of OS of EWS patients (n = 166), stratified in two groups according to their ABCA6 expression status in ‘high’ and ‘low’ (cut-off 22nd expression percentile). All EWS tumors were profiled on Affymetrix gene expression arrays. Mantel–Haenszel test. c, Comparative gene expression analysis of ABCA6 in EWS (grey color; n = 50) and other solid and hematologic (pediatric) cancers (n ≥ 20 per canter type). Gene expression data were generated on Affymetrix HG-U133Plus2.0 arrays, downloaded from public repositories, manually curated and jointly normalized using RMA and brainarray CDF. Data are displayed as box-plots: the horizontal bars represent median expression values, boxes the interquartile range, and whiskers the 10th–90th expression percentile. CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; R-ARMS pos, alveolar rhabdomyosarcoma fusion-positive; R-ARMS neg, alveolar rhabdomyosarcoma fusion-negative; pediatric AML, pediatric acute myeloid leukemia